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te list of study participSummary Introduction: To assess whether respiratory intermediate care units
(RICUs) are cost effective alternatives to intensive care units (ICUs) for patients with
exacerbation of chronic obstructive pulmonary disease (COPD).
Patients and methods: Multi-centre, prospective, bottom-up cost study
performed in 15 ICUs and 6 RICUs. COPD patients staying longer than 48 h were
recruited; those coming from other ICUs/RICUs, with immune-deficiency or stroke,
were excluded. After the ICU sample was standardised to the RICU distribution of the
reason-for-admission and infusion of a vasoactive drug on admission, 60 ICU patients
and 65 RICU patients remained, of the original 164 recruited. For each patient,
besides clinical data on admission and discharge, daily information about the
resources consumed were recorded and analysed in terms of their costs.
Results: Total cost per patient was lower in RICUs than in ICUs (754 vs. 1507 Euro;
Po0.0001). In all items, except drugs and nutrition, we found a significant lower
cost in RICUs. Dead patients were noticeably different in terms of disease severity
between ICUs and RICUs, while surviving ones were not.
Conclusions: Our study suggests that some COPD patients, less severe and with
pure respiratory failure, could be successfully and less costly treated in RICUs.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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ants is reported in Appendix A.
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An intensive care unit (ICU) is a valuable but
extremely expensive resource and cost contain-
ment has accordingly been deemed a mandatory
task.1 Strategies for controlling the cost of treating
critical patients should address the process of care,
both inside and outside the ICU. Admitting border-
line patients to intermediate care units instead of
ICUs has been proposed as an effective and
efficient policy.2 However, very few studies have
compared the costs of ICUs and intermediate units,
and no study makes such a comparison with a
bottom-up approach, which is considered the best
way of costing health care.3
Patients with acute exacerbation of chronic
obstructive pulmonary disease (COPD) often have
prolonged ICU stays, with a high risk of complica-
tions.4,5 Respiratory intermediate care units (RI-
CUs) have been proposed as cost effective
alternatives to ICUs for these patients.6–9
Within the framework of a multi-centre ICU
project carried out by GiViTI (Gruppo Italiano per
la Valutazione degli Interventi in Terapia Intensiva )
and aimed at estimating the costs of treating pre-
specified patient typologies by means of a bottom-
up approach, six RICUs collected data on patients
affected by acute exacerbation of COPD. The aim
was to compare ICUs and RICUs in terms of process
of care and costs for such patients.Methods
The first 10 patients over 14 years of age
admitted to the participating units from June to
October 1999 with an acute exacerbation of COPD
(defined according to the American Thoracic
Society criteria10) and who stayed in the unit
longer than 48 h were recruited.
For each patient, data on admission and dis-
charge characteristics, as well as daily information
about the use of drugs, infusions (including blood
and blood products), disposables, clinical support
services, and consultations from other depart-
ments, were recorded by means of a previously
validated electronic form. We limited data collec-
tion to resources associated with a weekly expen-
diture higher than 25 Euro.
The Nine Equivalents of nursing Manpower use
Score (NEMS),11 presence or absence of sepsis
(according to the ACCP/SCCM classification12),
were also recorded daily. All daily information
was collected until discharge or for a maximum of
21 days. Data collection was performed by means ofan electronic form that concurrently executed
more than 100 data validity checks. Data were also
reviewed at the co-ordinating centre and any doubt
was discussed with the single ICU.
Each item was expressed by its cost in Euro.
While the cost of drugs was easily obtained by
halving their retail price (the rebate companies
apply to hospitals in Italy), cost estimation for all
other items required ad hoc data collection. All
participating units were asked to provide the cost
of each item considered, as paid for in 2000. Since
not all units were able to provide this, we used
available figures to calculate mean costs for each
item and applied them to all units.
Since we found, as expected, different patient
mixes in ICUs and RICUs, we applied both the
restriction and the standardisation approach in
order to make the two samples comparable. More
specifically, we excluded from the analysis (restric-
tion) patients coming from other ICUs, because for
RICUs they are ‘‘step-down’’ patients while for ICUs
they are mostly ‘‘step-up’’ patients. We also
excluded patients with immune-deficiencies, as
well as those with stroke, because such patients
are seldom treated in RICUs. At this point, the ICU
sample was directly standardised to the distribu-
tion of the reason-for-admission, combined with
the infusion of a vasoactive drug on admission.
Direct standardisation allows to calculate the
hypothetical crude parameters (e.g., rates, means,
proportions, etc.) that a sample would have
provided if the distribution of a specific variable
(the factor of standardisation) had been the same
as a reference one (the standard). The rationale of
standardisation is to keep all the original sample in
the analysis, while weighting differently each
patient in order to yield a sample that is compar-
able to the one of interest. The rationale for
standardising to the reason-for-admission and the
presence of a vasoactive drug on admission was the
large (not surprising) difference between ICUs and
RICUs with respect to these variables.
Proportion was used as a descriptive statistic
for categorical and ordinal variables, while mean
and standard deviation (SD) were used for contin-
uous variables. Since the overall and specific costs
were subject to various outliers, we considered
the median and inter-quartile range (IQR) as
better descriptors of their distributions. Mantel–
Haenszel Chi-squared or Fisher exact test were
used to compare proportions; a global P lower than
0.05 was considered significant. Since we per-
formed multiple comparisons, we adopted the
Bonferroni correction of the P-value,13 which
yielded a cut-off for significance of 0.006 in each
single test.
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In total, 15 ICUs and 6 RICUs adhered to the
project, all of them in tertiary hospitals. All
Hospitals where the 15 participating ICUs were
located lacked RICUs. On the contrary, all the
hospitals where the 6 RICUs were located also had
an ICU.
The mean number of recruited patients per unit
was 5.6 (range: 3–10) for ICUs and 13.3 (range:
7–17) for RICUs. The restriction process led to the
exclusion of 24 ICU patients (29%) and 15 RICU
patients (19%), leaving 125 patients for the
comparison.
Patients’ characteristics on admission before and
after standardisation and restriction are shown in
Table 1. All the following reported analyses were
performed on the standardised and restricted
samples.
Since mortality was lower, though non-signifi-
cantly, in RICUs than in ICUs (7.7% vs. 16.9%,
P ¼ 0.12), we explored the possible differences
between alive and dead patients in the two types of
unit. Specifically, we analysed the length of stay,
the SAPS-II and the NEMS score, the average
number of days in high level of care,14 as well as
the average number of days with full respiratory
(mechanical ventilation) or cardiovascular (more
than one vasoactive drug) support. Table 2 shows
the results.
The total cost per patient was significantly lower
in RICUs than in ICUs (754 vs. 1507 Euro;
Po0.0001). In all the considered cost items except
drugs and nutrition we found a significant differ-
ence in the same direction between RICUs and
ICUs. The differences were particularly notable in
dead patients (Table 3). In order to better
characterise the differences in costs, Table 4 shows
resource consumption during stay, both in RICU and
ICU patients.Discussion
This is, to our knowledge, the first multi-centre
study designed to compare intensive care units and
intermediate care units in terms of case mix,
process of care, and costs. Since we considered
respiratory intermediate care units, we limited the
study to patients with exacerbated COPD. It is
important to underline that, although of the same
nature, ICUs studied were in hospitals that did not
have any intermediate care units, while study
RICUs were in hospitals that had ICUs. This means
that we compared two different health careorganisations: one in which high dependency
patients are admitted to ICUs and the other in
which some of these patients are admitted to
intermediate units.
Our results confirm that ICUs and RICUs admit
different kinds of patients, even within the same
diagnostic group such as COPD exacerbation. ICUs,
more often than RICUs, admit patients from other
hospitals or from hospital wards (i.e., more com-
plex patients), more patients with multiple organ
failure, with high SAPS-II score and no associated
diagnosis (i.e., more acutely ill patients), and with
pneumonia (a more serious cause of COPD exacer-
bation). On the contrary, RICUs, more often than
ICUs, admit patients just for monitoring (i.e., more
clinically stable patients). The observed higher
prevalence of home oxygen therapy and tracheot-
omy on admission among RICU patients could mean
that they have a longer history of COPD, i.e.,
patients who were more aware of their condition
and consequently came to hospital earlier in a less
severe state.
Beyond these differences, we found that ICUs
located in hospitals in which an intermediate care
facility is lacking admit a proportion of less severe
COPD patients, with pure respiratory failure, that
could be admitted to an RICU. The problem is
obviously to know whether such patients could be
admitted to an RICU and, in such a case, whether
they would receive different care, if this would
yield a substantial saving, and if this would affect
their outcome.
It has already been argued that some of the
invasiveness of the ICU approach could be helpfully
reduced.15,16 Reports from well-conducted rando-
mised clinical trials17–19 and from a recent meta-
nalysis20 showed that non-invasive ventilation
performed in ICUs can reduce mortality, nosocomial
pneumonia and length of stay in selected patients
with acute exacerbation of COPD. Albeit important
for guiding clinical practice, our doubt remains
unanswered: is the assistance given to these
patients by RICUs as effective as that given by
ICUs, possibly at a lower cost?
This is the first study that addresses such a
question in real life. Moreover, the comparison is
based on data collected through a previously
validated form, in a bottom-up fashion. Notor-
iously, the bottom-up approach, that calls for single
patient data collection, is considered the best
method for costing health care.21
From our results we can argue that a subset of
less severe patients with acute exacerbation of
COPD could be treated in an intermediate setting
(RICU) at a lower cost, if compared to an ICU, and
without affecting their clinical outcome. The
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Table 1 Characteristics of patients before and after standardisation and restriction procedures.
Before restriction and
standardisation
After restriction and
standardization
ICU RICU ICU RICU
Number of patients 84 80 60 65
Age, mean (SD) 71.3 (7.9) 70.8 (8.1) 70.0 (8.7) 71.2 (8.4)
Gender, female (%) 20.2 26.3 23.2 27.7
Provenience of patient (%)
Same hospital 57.1 73.8 46.8 75.4
Emergency room 45.2 42.5 55.8 52.3
Hospital ward 44.1 38.8 44 47.7
Operating theatre 1.2 0 0.3 0
Other ICU 9.5 18.8 0 0
Concomitant diagnosis (%)
None 19.1 5 20.2 6.2
One 56 77.5 67.6 76.9
Two 20.2 16.3 12.2 15.4
Three 3.6 1.3 0 1.5
Four 1.2 0 0 0
Reason for admission (%)
Monitoring 1.2 11.3 12.3 12.3
Respiratory weaning 0 0 0 0
Single organ failure 82.1 85 84.6 84.6
Multiple organ failure 16.7 3.8 3.1 3.1
Organ failure on admission (%)
Respiratory 98.8 98.8 87.7 87.7
Cardiovascular 14.3 3.8 3.1 3.1
Neurological 2.4 0 0 0
Glasgow Coma Score, mean (SD) 12.4 (2.7) 13.8 (1.9) 12.5 (2.9) 13.6 (2.1)
SAPS-II score, mean (SD) 33.6 (11.2) 25.7 (8.4) 30.0 (11.9) 25.8 (8.9)
Vasoactive drugs on admission (%) 15.5 1.3 1.5 1.5
Tracheotomy tube on admission (%) 6 13.8 2.3 6.2
Pneumonia as cause of exacerbation (%) 29.8 18.8 26.3 12.3
Home oxygen treatment (%) 51.3 75.3 44.9 74.6
Length of ICU stay, median (range) 8 (70) 8.5 (40) 7 (70) 8 (40)
Length of hospital stay, median (range) 17 (89) 15 (160) 16 (89) 13 (39)
ICU, intensive care unit; RICU, respiratory intermediate care unit; SD, standard deviation; SAPS-II, simplified acute physiology
score II.
Costs of the COPD 897observed cost saving (50%) was due to a different
philosophy of care. Indeed, it was not simply a
matter of invasive versus non-invasive ventilation.
As Table 4 shows, the non-invasive approach of
RICUs was extended to almost all procedures: from
monitoring to nutrition, from laboratory to imaging
tests. Interestingly, we found a higher use of
steroids in RICUs, this explains the higher cost for
drugs in these units. Recent randomised trials
showed that the use of systemic steroids in patients
with acute exacerbation of COPD shortens length of
stay and restores lung function faster.22,23 On the
other hand, high doses of these drugs or prolongedtreatments increase the risk of side effects, while
not improving outcome.23,24
The RICUs’ non-invasive approach reduced the
need for nursing care, as shown by lower NEMS
scores, with the subsequent further reduction in
cost. Since NEMS can be converted in nursing time,8
it is possible to estimate that each COPD patient
admitted to an RICU instead of an ICU saves on
average 10.5 nurses’ working hours. By applying the
cost of nursing in Italy (19.5 Euro/h), this means a
saving of 205 Euro per patient. In the end, putting
together variable costs and nursing costs, the
estimated saving would be 957 Euro per patient.
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Table 2 Differences between alive and dead patients in the two types of unit.
RICU ICU
Alive Dead Alive Dead
Length of stay, median (IQR) 8 (4–12) 4 (2–10) 7 (4–15) 9 (6–51)
Reason for admission: monitoring (%) 10.0 40.0 15.9 0.0
Reason for admission: single OF (%) 86.7 60.0 81.4 93.5
Cardiovascular failure on admission (%) 3.3 0.0 2.7 6.6
Pneumonia as cause of exacerbation (%) 11.7 20.0 25.8 29.1
SAPS-II score, mean (SD) 25.4 (8.7) 30.6 (11.3) 29.3 (13.0) 34.9 (8.9)
NEMS score, mean (SD) 209 (135) 147 (92) 241 (187) 414 (217)
Days in HLC, mean (SD) 6.4 (5.4) 3.0 (2.7) 6.8 (6.5) 12.0 (6.2)
Days in full respiratory support, mean (SD) 6.4 (5.4) 2.8 (2.8) 6.6 (6.5) 11.9 (6.1)
Days in full cardiovascular support, mean (SD) 0.02 (0.1) 0.0 () 0.4 (1.3) 0.4 (0.8)
ICU, intensive care unit; RICU, respiratory intermediate care unit; IQR, inter-quartile range; OF, organ failure; SD, standard
deviation; SAPS-II, simplified acute physiology score II;25 NEMS, nine equivalents of nursing manpower use score;11 HLC, high
level of care.14
Table 3 Cost comparison (Euro per patient).
RICU ICU P Dead Alive
RICU ICU RICU ICU
Drugs 321.21 243.58 NS 227.8 340.8 329.0 232.6
Enteral and parenteral nutrition 23.66 106.44 NS 52.7 188.7 21.2 94.5
Infusions 8.45 86.90 o0.0001 21.1 185.5 7.4 69.6
Procedures 70.00 283.03 o0.0001 25.2 586.4 73.7 226.3
Instrumental examinations 65.65 128.84 0.0007 82.7 271.4 64.2 106.1
Laboratory tests 240.32 599.76 o0.0001 271.3 941.8 237.7 544.3
Total cost 754.42 1507.23 o0.0001 714.0 2662.4 757.8 1316.5
ICU, intensive care unit; RICU, respiratory intermediate care unit.
G. Bertolini et al.898Even though our study design does not allow
any inference about the outcome, our results
suggest that the non-invasive approach typical of
RICUs, while lowering the cost of care, does
not negatively affect clinical outcome of COPD
patients.
A limitation of this study is the role of standardi-
sation and restriction in rendering the two samples
clinically comparable. Standardisation could prove
unsuccessful when applied to small samples.
Indeed, while the original case mix differences
dramatically vanished after standardisation and
restriction, some discrepancies remained.
Table 1 shows that in ICUs, patients were more
often transferred form other hospitals, pneumonia
was more often a reason for exacerbation, and the
severity of illness SAPS-II score25 was higher. These
differences are signs of a more severe and complex
case mix. In order to verify whether the estimated
differences in costs can be ascribed to thesedifferences in case mix, we performed a sensitivity
analysis on alive patients with pure respiratory
failure, without vasoactive drugs on admission,
without pneumonia, and with SAPS II score lower
than 32. Costs in RICUs remained lower, by 40%,
than in ICUs (data not shown). Furthermore, the
analysis of alive and dead patients reveals impor-
tant dissimilarities between ICUs and RICUs. It is
interesting to see that, while patients who even-
tually died were treated in ICUs more aggressively
and more costly than patients who survived, this
did not happen in RICUs (for example, median
length of stay for patients who died was 4 and 9
days in RICUs and ICUs respectively, and mean
number of days under high level of care for patients
who died was 3 and 12 in RICUs and ICUs,
respectively; Tables 2 and 3). This could mean that
there also exists a proportion of more severe COPD
patients admitted to RICUs who might be usefully
admitted to ICUs instead.
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Table 4 Resource consumption in ICUs and RICUs
(percentage of patients).
Resource ICUs (60
patients)
RICUs
(65
patients)
Enteral nutrition 60.4 9.2
Parenteral nutrition 41.9 15.4
Central venous catheters 61.2 21.5
Other invasive catheters 48.1 3.1
Invasive arterial pressure
monitoring sets
44.9 0.0
Circuits for mechanical
ventilation
96.5 81.5
Antibiotics 87.6 90.8
Steroids 22.3 60.0
Neuromuscular blocking
agents
26.6 0.0
Sedatives 51.8 26.2
Bronchodilators 88.9 81.5
Cardiovascular drugs 73.0 56.9
Diuretics 84.1 80.0
Endoscopies 7.1 9.2
CT scans 9.6 1.5
Chest X-rays 96.5 92.3
General blood
investigations
98.2 58.5
Coagulation tests 92.7 47.7
Cardiac enzymes 92.9 44.6
Bacteriology 60.7 53.8
Serology/virology 33.4 6.2
Blood gases 98.2 100
Specialists’ visits 45.0 43.1
Chest physiotherapy 33.6 18.5
ICU, intensive care unit; RICU, respiratory intermediate
care unit.
Costs of the COPD 899In conclusion, a fraction of COPD patients, mainly
less severe ones and those with pure respiratory
failure, could be successfully and less costly
admitted to RICUs. In hospitals in which an
intermediate care facility is lacking, some of these
patients are admitted to ICUs. Even though these
patients account for a small proportion of the ICU
sample, this seems a waste of resources.
While a definite answer could come from a
randomised trial, our study suggests that the avail-
ability of an RICU allows both substantial cost savings
and freeing ICU beds. Thus, setting up RICUs should
be encouraged, especially in tertiary hospitals.Acknowledgements
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